Results 11 to 20 of about 10,664 (186)

Effectiveness and safety of canakinumab in cryopyrin-associated periodic syndrome: a retrospective study in China

Pediatric Rheumatology Online Journal
Objective Cryopyrin-associated periodic syndrome (CAPS) is characterized by excessive IL-1β release resulting in systemic and organ inflammation. As an anti-IL-1 agent, canakinumab has been approved with all CAPS phenotypes in USA and European countries.
Xiaona Zhu, Jiaqi Fan, Yanyan Huang, Yongbin Xu, Zhi Yang, Ruohang Weng, Ying Luo, Jun Yang, Tingyan He   +8 more
doaj   +2 more sources

CANOPY-N: A Phase 2 Study of Canakinumab or Pembrolizumab, Alone or in Combination, as Neoadjuvant Therapy in Patients With Resectable, Stage IB–IIIA NSCLC [PDF]

JTO Clinical and Research Reports
Introduction: Canakinumab is a human monoclonal anti–interleukin-1β antibody with the potential to enhance the activity of programmed death-ligand 1 inhibitors by inhibiting protumor inflammation.
Jay M. Lee, MD, Jean-Louis Pujol, MD, PhD, Jun Zhang, MD, PhD, Oleg Leonov, MD, PhD, Masahiro Tsuboi, MD, PhD, Edward S. Kim, MD, MBA, Calvin Ng, MD, Nicolas Moreno-Mata, MD, PhD, Amy Cummings, MD, PhD, Ilhan Hacibekiroglu, MD, Abidin Sehitogullari, MD, Nirmal Veeramachaneni, MD, Cathy Spillane, PhD, Jiawei Duan, PhD, Claudia Bossen, PhD, Alexander Savchenko, MD, PhD, Chiara Lobetti-Bodoni, MD, PhD, Tony Mok, MD, Pilar Garrido, MD   +18 more
doaj   +2 more sources

Pharmacokinetic and pharmacodynamic properties of canakinumab in patients with gouty arthritis

Journal of Clinical Pharmacology, 2013
Pharmacokinetics and pharmacodynamics of the anti ]interleukin (IL)]1b monoclonal antibody, canakinumab, in gouty arthritis patients from three studies are reported.
Gangadhar Sunkara, Dan Howard
exaly   +2 more sources

Canakinumab for the treatment of adult-onset Still’s disease

Expert Review of Clinical Immunology, 2020
Introduction: Adult-onset Still’s disease (AOSD) is a rare multisystem autoinflammatory disorder of unknown etiology, with clinical and biological similarities with the juvenile form (sJIA). The pivotal role of interleukin (IL)-1 gives rise to the use of
Paolo Sfriso, Sara Bindoli, Andrea Doria   +2 more
exaly   +2 more sources

Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients

Modern Rheumatology, 2020
Background: Little is known about the long-term efficacy and safety of canakinumab in paediatric FMF patients. Aim: To present the single centre experience of colchicine-resistant paediatric-onset FMF patients who were treated with canakinumab by off ...
Nesrin Gülez, Balahan Makay, Betul SÖZERİ   +2 more
exaly   +2 more sources

Canakinumab in the treatment of systemic juvenile idiopathic arthritis: a retrospective single center study in China

Frontiers in Pediatrics
ObjectiveSystemic juvenile idiopathic arthritis (sJIA) is characterized by excessive production of proinflammatory cytokines. As an anti-IL-1 agent, canakinumab has been approved in the USA and Europe for the treatment of sJIA patients aged ≥2 years ...
Xiaona Zhu, Ruohang Weng, Yanyan Huang, Yongbin Xu, Jun Yang, Tingyan He   +5 more
doaj   +2 more sources

Canakinumab and cardiovascular outcomes: results of the CANTOS trial

Journal of Community Hospital Internal Medicine Perspectives, 2018
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced in response to pathogen mediated tissue injury. Among the IL-1 cytokine family, IL-1 β results in upregulation of genes responsible for boosting immune ...
Syed Raza Shah, Zainab Abbasi, Mazia Fatima, Rohan Kumar Ochani, Waqas Shahnawaz, Muhammad Asim Khan, Syed Arbab Shah   +6 more
doaj   +2 more sources

Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab

Journal of Dermatological Treatment, 2023
Schnitzler syndrome (SchS) is a rare autoimmune and inflammatory disease mediated by interleukin-1 beta (IL-1β). Recurrent monoclonal gammopathy and chronic urticarial rash are the symptoms required for diagnosis according to the Strasbourg criteria. The
Angel Luis Salcedo-Mingoarranz, María Dorado-Fernández, Sofía García-Martínez, Paz Collado-Ramos, Nicolás Silvestre-Torner   +4 more
doaj   +2 more sources

Canakinumab treatment patterns in sJIA, FMF, TRAPS, and MKD/HIDS: real-world insights from a Belgian non-interventional study [PDF]

BMC Rheumatology
Background Canakinumab, an IL-1β inhibitor, has demonstrated long-term efficacy and safety in patients with sJIA, FMF, TRAPS, and MKD/HIDS who experience inadequate disease control with conventional treatments. This non-interventional study aimed to gain
Michel Moutschen, Cécile Boulanger, Joke Dehoorne, Rik Joos, Florence Roufosse, Vito Sabato, Jeroen van der Hilst, Eleonore Maury, Hilde Rabijns, Marijn Witterzeel, Carine Wouters   +10 more
doaj   +2 more sources

Neonatal-onset multisystem inflammatory disease caused by a de novo NLRP3 gene mutation: a case report and literature review [PDF]

Frontiers in Pediatrics
BackgroundNeonatal-onset multisystem inflammatory disease (NOMID) is a rare autoinflammatory disease caused by NLRP3 mutations, leading to excessive interleukin-1β activation and potential irreversible organ damage.Case descriptionWe report a female ...
Lingxia Zhao, Lingkong Zeng, Wenhao Yuan
doaj   +2 more sources